BioNexus Gene Lab Corp. Proceeds from (Repayments of) Related Party Debt
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from (Repayments of) Related Party Debt of $75.13 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt · last filed 2026-08-14
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for the quarter ending 2026-06-30 was -$5.58K.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for the quarter ending 2026-03-31 was $80.72K.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for the quarter ending 2025-12-31 was -$497.00.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for the quarter ending 2025-09-30 was $34.19K.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for fiscal 2025 was $32.30K, a 712.70% increase from fiscal 2024.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for fiscal 2024 was $3.98K.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for fiscal 2019 was -$1.06K, a 173.58% decline from fiscal 2018.
- BioNexus Gene Lab Corp. proceeds from (repayments of) related party debt for fiscal 2018 was $1.44K.
| Period end | Proceeds from (Repayments of) Related Party Debt 3 month | Proceeds from (Repayments of) Related Party Debt 6 month | Proceeds from (Repayments of) Related Party Debt 9 month | Proceeds from (Repayments of) Related Party Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $75.13K 10-Q · filed 2026-08-14 | $74.64K derived: sum of 3 quarters · filed 2026-08-14 | $108.82K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $80.72K 10-Q · filed 2026-05-15 | $80.22K derived: sum of 2 quarters · filed 2026-05-15 | $114.41K derived: sum of 3 quarters · filed 2026-05-15 | $113.88K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$497.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $33.69K derived: sum of 2 quarters · filed 2026-04-14 | $33.16K derived: sum of 3 quarters · filed 2026-08-14 | $32.30K 10-K · filed 2026-04-14 |
| 2025-09-30 | $34.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $33.66K derived: sum of 2 quarters · filed 2026-08-14 | $32.80K 10-Q · filed 2025-11-14 | $31.41K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$525.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.39K 10-Q · filed 2026-08-14 | -$2.77K derived: sum of 3 quarters · filed 2026-08-14 | -$199.75K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$860.00 10-Q · filed 2026-05-15 | -$2.25K derived: sum of 2 quarters · filed 2026-05-15 | -$199.23K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$1.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$198.37K derived: sum of 2 quarters · filed 2026-04-14 | $3.98K 10-K · filed 2026-04-14 | |
| 2024-09-30 | -$196.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.36K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $202.34K 10-Q · filed 2025-08-18 | |||
| 2020-06-30 | -$3.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$371.00 10-Q · filed 2020-08-11 | -$552.00 derived: sum of 3 quarters · filed 2020-08-11 | -$650.00 derived: sum of 4 quarters · filed 2020-08-11 |
| 2020-03-31 | -$368.00 10-Q · filed 2020-05-08 | -$549.00 derived: sum of 2 quarters · filed 2020-05-08 | -$647.00 derived: sum of 3 quarters · filed 2020-05-08 | |
| 2019-12-31 | -$181.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | -$279.00 derived: sum of 2 quarters · filed 2020-03-31 | -$1.06K 10-K · filed 2020-03-31 | |
| 2019-09-30 | -$98.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$880.00 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | -$782.00 10-Q · filed 2020-08-11 | |||
| 2018-12-31 | $1.27K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | -$3.33K derived: sum of 2 quarters · filed 2020-03-31 | $1.44K 10-K · filed 2020-03-31 | |
| 2018-09-30 | -$4.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $169.00 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $4.78K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |